Therefore, the chances of ADE are low in COVID cases, and no ADE has been observed in COVID-19 infection
Balogh M, Varga BK, Kardi D, Riba P, Puskr Z, Kozsurek M et al (2019) Similarity and dissimilarity in antinociceptive effects of dipeptidyl-peptidase 4 inhibitors, Diprotin A and vildagliptin in rat inflammatory pain models following spinal administration
doi: 10.3389/fmolb.2025.1724944 Received 14 October 2025 Revised 18 November 2025 Accepted 30 November 2025 Published 18 December 2025 Volume 12 - 2025 Edited by Maria Barile, University of Bari Aldo Moro, Italy Reviewed by Anna Maria Giudetti, University of Salento, Italy Maria Tolomeo, National Research Council (CNR), Italy Updates Copyright 2025 Schrder, Jalilvand, Kahl, Kaiser and Liebau
When you stop taking Wegovy, its appetite-regulating effects will wear off
Scientific Backing Research backs up these personal stories with solid evidence
In fact, it can affect anyone, especially those who eat irregularly, follow restrictive diets, or experience frequent blood sugar fluctuations
![tirzepatide phase 2 Efficacy of in (GPGB; [14]) and phase 3 (SURPASS-1 LLY -0.60% today as Lilly's](https://www.researchgate.net/publication/363201315/figure/fig3/AS:11431281082605778@1662084799021/Efficacy-of-tirzepatide-in-phase-2-GPGB-14-and-phase-3-SURPASS-1-to-5-15-19.png)
![tirzepatide phase 2 Efficacy of in (GPGB; [14]) and phase 3 (SURPASS-1 LLY -0.60% today as Lilly's](https://pbs.twimg.com/media/G1GF0bCWMAAYORq.jpg)
![tirzepatide phase 2 Efficacy of in (GPGB; [14]) and phase 3 (SURPASS-1 LLY -0.60% today as Lilly's](https://i.postimg.cc/jjmwvxS2/Tirzepatide-Results-Timeline-Week-by-Week-Guide.jpg)
![tirzepatide phase 2 Efficacy of in (GPGB; [14]) and phase 3 (SURPASS-1 LLY -0.60% today as Lilly's](https://cdn.atpoc.com/cdn/activity/breakingmed/image/89290.jpeg)
![tirzepatide phase 2 Efficacy of in (GPGB; [14]) and phase 3 (SURPASS-1 LLY -0.60% today as Lilly's](https://b1167102.smushcdn.com/1167102/wp-content/blogImages/10222025/tirz04.jpg?lossy=2&strip=1&webp=1)
![tirzepatide phase 2 Efficacy of in (GPGB; [14]) and phase 3 (SURPASS-1 LLY -0.60% today as Lilly's](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54bd/10087310/ebe6b2d90ee1/DOM-25-3-g002.jpg)
![tirzepatide phase 2 Efficacy of in (GPGB; [14]) and phase 3 (SURPASS-1 LLY -0.60% today as Lilly's](https://lookaside.fbsbx.com/lookaside/crawler/media/?media_id=1119392386880828)
